Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Advances in systemic therapies for triple negative breast cancer
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance
F Weiss, D Lauffenburger, P Friedl - Nature Reviews Cancer, 2022 - nature.com
Resistance to therapeutic treatment and metastatic progression jointly determine a fatal
outcome of cancer. Cancer metastasis and therapeutic resistance are traditionally studied as …
outcome of cancer. Cancer metastasis and therapeutic resistance are traditionally studied as …
Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a rare cancer, characterized by high metastatic
potential and poor prognosis, and has limited treatment options. The current standard of …
potential and poor prognosis, and has limited treatment options. The current standard of …
Multi-omic machine learning predictor of breast cancer therapy response
Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …
microenvironment. The composition of these tumour ecosystems and interactions within …
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad… - The Lancet …, 2022 - thelancet.com
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from …
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
DM Wolf, C Yau, J Wulfkuhle, L Brown-Swigart… - Cancer cell, 2022 - cell.com
Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-
SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer …
SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer …
[HTML][HTML] Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology
Abstract Models that recapitulate the complexity of human tumors are urgently needed to
develop more effective cancer therapies. We report a bank of human patient-derived …
develop more effective cancer therapies. We report a bank of human patient-derived …
Neoadjuvant checkpoint blockade for cancer immunotherapy
BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …
[HTML][HTML] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guidelines provide updated state-of-the-art recommendations
on management of early breast cancer (diagnosis, treatment and follow-up), compiled by a …
on management of early breast cancer (diagnosis, treatment and follow-up), compiled by a …